Background: Following induction therapy with a calcineurin inhibitor (CNI) in severe ulcerative colitis, transitioning to vedolizumab as maintenance therapy could be an option.
| INTRODUC TI ON
Ulcerative colitis is a chronic inflammatory disease of the colon with varying degrees of disease severity as defined by several clinical, biochemical and endoscopic parameters. 1, 2 The options for the medical management of patients with severe steroid-refractory ulcerative colitis are limited and include calcineurin inhibitors (CNIs) or infliximab, [1] [2] [3] [4] [5] [6] with infliximab being the predominant agent used in such a setting, due to its ease of administration and familiarity with its use by prescribing physicians. 7 Patients who are successfully induced with infliximab continue to maintenance therapy with this drug. Secondary to its increased use in ulcerative colitis, patients failing infliximab are becoming more prevalent. 8 While highly effective at inducing remission in patients with ulcerative colitis, 3, 5 protracted use of CNIs is limited by adverse events, including infection, nephrotoxicity, hypercholesterolaemia and hypertension. Consequently, their use in inflammatory bowel disease has been limited to induction therapy. Patients who are successfully induced with CNIs in the setting of severe steroid-refractory ulcerative colitis are bridged to azathioprine for maintenance therapy. 1, 2 Previously, patients who had failed or were intolerant to thiopurines were not considered candidates for calcineurin therapy due to the absence of effective maintenance therapy.
Vedolizumab is an effective and safe medication approved for induction and maintenance therapy in ulcerative colitis. 9, 10 Vedolizumab's impressive safety data 10 makes it an ideal candidate agent for use as maintenance therapy in combination with the fast-acting CNIs as induction therapy. Our group previously reported our preliminary data on the potential safety and efficacy of this sequential combination regimen. 11 That study, however, was limited by the small number of patients and heterogeneous population included (11 patients with ulcerative colitis and nine patients with Crohn's disease) and as such encouraged further larger observational cohorts using this treatment strategy. In this study, by enrolling a significant number of subsequent patients with steroid-refractory ulcerative colitis, we are now able to cumulatively report on long-term safety and efficacy in a more homogenous population.
We describe the largest cohort of patients with steroid-refractory ulcerative colitis successfully induced with CNIs who were then transitioned to vedolizumab maintenance therapy and show that such a management strategy is effective and safe over a long follow-up period.
| ME THODS

| Study design and patients
We performed a retrospective single-centre observational study of adult ulcerative colitis patients followed at the University of Chicago Inflammatory Bowel Disease Center, a large tertiary referral centre.
All patients with severe steroid-refractory ulcerative colitis who received a CNI (ciclosporin or tacrolimus) as induction therapy followed by maintenance therapy with vedolizumab between January 2014 and December 2018 were included. All patients responded to IV ciclosporin or oral tacrolimus and received at least one vedolizumab infusion while on calcineurin therapy.
| Medications
All patients were treated with either IV ciclosporin or oral tacrolimus.
Ciclosporin was given as a continuous infusion at an initial dose of 2-4 mg/kg/d, aiming for serum trough levels of 300-400 ng/mL.
In case of response (decrease of bowel movement frequency by 50%
with the absence of haematochezia), a switch to an oral formulation was performed using a total daily dose equivalent to twice the 24 hours intravenous dose.
Tacrolimus was started orally at 0.1 to 0.2 mg/kg/d, targeting a blood concentration of 10-15 ng/g. The choice of the CNI used, ciclosporin or tacrolimus, was made according to the attending physician discretion.
In patients who responded to calcineurin induction, vedolizumab was administered as 300 mg infusions with standard loading doses; weeks 0, 2 and 6, and then every 8 weeks. In case of continued clinical activity or objective evidence of continued inflammation (laboratory or endoscopic), vedolizumab could be prescribed every 4 weeks following induction. Following the induction infusions of vedolizumab the CNI was tapered off. In the case of vedolizumab failure, subsequent treatments were documented, as well.
| Data collection
At inclusion, the following characteristics were recorded for each patient: sex, age, disease duration, smoking status, disease extent according to the Montreal classification, prior received treatments (steroids, thiopurine, methotrexate, infliximab, adalimumab, golimumab), endoscopic activity measured with the endoscopic Mayo subscore, C-reactive protein (CRP), haemoglobin and albumin levels.
All patients included had a clinic follow-up of at least 3 months.
| Endpoints
The primary endpoint was colectomy-free survival. Secondary endpoints included survival without vedolizumab discontinuation as well as clinical, steroid-free, biochemical remission at week 14 as well as time to endoscopic remission and rate of endoscopic remission at 12 months. Clinical remission was defined as the absence of blood in the stools and <3 stools per day with the lack of abdominal pain.
Biochemical remission was defined by a normal CRP level (<5 mg/L).
Endoscopic remission was defined as an Mayo endoscopic score of 0 or 1. In addition, all adverse events were described. The study was approved by the University of Chicago Institutional Review Board. 
| Statistical analysis
Descriptive statistics for demographic and clinical characteristics include median (IQR) for continuous variables and frequency distributions for categorical data. Kaplan-Meier curves were generated for time-to-event data, that is, time from first vedolizumab infusion until colectomy or cessation of vedolizumab treatment.
Patients who did not have a colectomy or who were still on vedolizumab were censored as of the date of the last follow-up.
Cox regression models were fit to examine the effects of different covariates on time to colectomy and vedolizumab cessation.
Covariates analysed included age, sex, smoking status, disease extent, pre-vedolizumab treatments, clinical and biochemical remission at week 14, as well as haemoglobin, CRP and albumin. Due to the limited number of events, models for time to colectomy or vedolizumab cessation included only one covariate at a time to avoid overfitting.
| RE SULTS
| Patients
A total of 71 patients (59% male) were treated with vedolizumab after induction therapy with CNIs for severe steroid-refractory ulcerative colitis. Eighty-five per cent (n = 60) of patients had previously been exposed to TNF antagonists' medications. Most had extensive disease (72%); the median disease duration was 44.1 months (IQR 15.2-115). Truelove and Witts criteria for acute severe ulcerative colitis (ASUC) were present in 76% (n = 54) of patients. Moderate to severe endoscopic disease was present in 97% of patients. Patients were followed for a median time of 25 months (IQR 16-36).
| Study medications
Sixty-eight per cent of patients (n = 48) received ciclosporin, and 32% (n = 23) of patients received tacrolimus. The CNI was continued for a median duration of 3.5 months (IQR 2.4-5.4). The majority (79%, n = 55) were induced with CNIs as inpatients, with ciclosporin being the drug of choice in most inpatients (88%, n = 48). Vedolizumab was started after a median of 29 days (IQR 16-44) from the initiation of the CNI. Vedolizumab was dose escalated to infusions every 4 weeks in 44% of patients. The median time to dose escalation was 5.7 months (IQR 4.1-8.2). Table 1 describes the baseline characteristics of the study cohort allocated according to the CNI used.
| Efficacy
Thirty patients (42%) underwent colectomy during the followup period. Colectomy-free survival rates from vedolizumab initiation were 93% at 3 months, 67% at 1 year and 55% at 2 years ( Figure 1A ). Only lack of clinical remission at week 14 was associated with colectomy (P = 0.023). There was no significant difference in colectomy rates between anti-TNF naïve patients and anti-TNF experienced patients, P = 0.79 ( Figure 1B) . Likewise, choice of the CNI used to induce remission was not associated with colectomy rates (P = 0.91). Patients meeting Truelove and Witts criteria for ASUC had numerically higher colectomy rates at 3 months and 1 year when compared to patients not meeting these criteria (9.5% and 37.1% vs 6.25% and 19.65% respectively), but this difference was not statistically significant (P = 0.8). Table 2 describes the baseline characteristics of patients with and without ASUC.
At the end of induction with vedolizumab at week 14, 50% of patients were in clinical remission, and 62% of patients were in biochemical remission with a normal CRP. Steroid-free remission rates were 27%, 43% and 76% at 3 months, 12 months and 24 months respectively.
Sixty-three per cent of patients were still on vedolizumab 6 months after induction. After 1 and 2 years, 43% and 28% of patients were still on vedolizumab respectively ( Figure 1C ). Both lack of clinical and biologic remission at week 14 were associated with vedolizumab discontinuation (P = 0.0003 and P = 0.003 respectively). Previous TNF antagonist therapy was not associated with an increased rate of vedolizumab discontinuation (P = 0.86). Data regarding endoscopic remission were available for 44 participants (61.9% of the study cohort), Twenty-one patients (48%) reached the endpoint of endoscopic remission during follow-up. The cumulative rate of endoscopic remission at 12 months was 20.9%.
| Drug therapy following discontinuation of vedolizumab
Thirty-one patients (44%) were transitioned to another drug after failing vedolizumab maintenance therapy. Seventeen patients were transitioned to an anti-TNF (71% infliximab); of these 17 patients, 15
(88%) had previously been on anti-TNF therapy, and 12 (71%) of these patients averted colectomy at the end of follow-up. Eleven patients were transitioned to tofacitinib. Eight (73%) of these patients had previously been on anti-TNF therapy, and six (55%) averted colectomy at the end of follow-up. Three patients were transitioned to ustekinumab. Two of these patients were previously on anti-TNF therapy, and two patients averted colectomy at the end of follow-up. Of these 31 patients who failed vedolizumab and transitioned to another drug, 20 (65%) averted colectomy at the end of follow-up. Colectomy-free survival times were similar after excluding patients who received other biologics after vedolizumab failure ( Figure 1A ). The median time to switch in therapy was 7.1 months (IQR 3.7-14.3) from vedolizumab initiation.
| Adverse events
Eighteen patients (25.4%) experienced adverse events. No mortality events were recorded during the follow-up period. In addition, all adverse events documented occurred while on CNIs, with none of the adverse events leading to discontinuation of the drug. The most common adverse event was acute kidney injury in eight patients (11.3%) ( Table 3 ).
| D ISCUSS I ON
In this study, we have shown that patients with severe steroid-refractory ulcerative colitis induced with CNIs and then transitioned to maintenance therapy with vedolizumab avoided colectomy in 67% of cases after 12 months and in 55% of cases after 2 years. Such a F I G U R E 1 A, Kaplan Meier curve of colectomy free survival for all patients and after excluding patients who received other biologics after vedolizumab failure. B, Kaplan Meier of colectomy free survival for patients exposed and not exposed to TNF antagonists. C, Kaplan Meier curve of time to vedolizumab discontinuation The second study by Pellet G et al 12 was a multicentre retrospective study from France. In this study, information was collected on 39 patients with steroid-refractory UC. The authors reported that after a median follow-up period of 11 months, 11 patients (28%) underwent colectomy and that patients meeting Truelove and Witts criteria for ASUC had higher colectomy rates when compared to patients who did not meet these criteria. While both studies reported on the feasibility of combination treatment with CNIs and vedolizumab to induce and maintain remission, larger observational studies are needed to better explore the efficacy and safety of such a strategy before advocating for its use in everyday practice.
In our large patient cohort with prolonged follow-up time, we have shown the safety and efficacy of such a treatment strategy. We chose colectomy-free survival as our primary endpoint as colectomy is an unambiguous event in a retrospective cohort series. Indeed, our study showed that in this very sick cohort of patients, a substantial proportion of patients were able to avoid colectomy in the short and long term by inducing patients with CNIs and transitioning to vedolizumab as maintenance therapy. Unlike the study by Pellet G et al 12 in our patient cohort, there was no significant difference between patients who met Truelove and Witts criteria for ASUC and those that did not in regards to colectomy free survival (P = 0.8). However, patients with ASUC did have numerically higher colectomy rates at 3 months and 1 year when compared to those without ASUC (9.5% and 37.1% vs 6.25% and 19.65% respectively). The study was likely underpowered to detect a difference, especially as the group without ASUC was relatively small at only 17 patients. It is also possible that as this study only included patients who had already responded to ciclosporin induction that colectomy rates between groups might have been attenuated.
We also looked at the time to vedolizumab discontinuation, and we have shown that despite a significant number of patients failing 16 Over time, even if patients averted colectomy, patients who still had clinical disease with endoscopic activity or were corticosteroid dependent were switched to other therapies. It is plausible that over a long follow-up period, a substantial number of patients will not reach management targets and will be switched to other therapies as these become available and treatment targets become more stringent. Patients who discontinued vedolizumab were able to successfully transition and regain response with other therapies, mainly tofacitinib and infliximab.
Interestingly, many patients transitioned to anti-TNFs after failing vedolizumab maintenance therapy were previously treated with an anti-TNF. Due to the retrospective nature of our study, we were unable to document the reason why anti-TNF therapy was stopped for a large proportion of these patients. Some patients had a distant history of anti-TNF use, and, as many of these patients were referred from outside institutions, no further data were available to us in order to clarify the reason behind anti-TNF discontinuation.
Likewise, due to the small number of patients who transitioned to further therapy with anti-TNFs and the lack of historical data for many of these patients, these results, while interesting, should be exploratory. Further studies should be performed looking into the possibility of 'circling back' to prior therapies in order to establish the efficacy of such a treatment strategy.
Inducing remission with CNIs and transitioning to vedolizumab maintenance therapy is becoming more relevant as more patients with ulcerative colitis now have a history of previous exposure and failure to anti-TNFs and azathioprine. 8 Likewise, since the publication of the CYSIF and CONSTRUCT trials, 17, 18 which demonstrated similar short-term response rates between infliximab and ciclosporin in the setting of acute severe ulcerative colitis, infliximab has emerged as the predominant agent used in such patients, 7 and more patients are presenting to tertiary care centres after failing infliximab. 8 A potential reason for nonresponse to infliximab is secondary loss of serum proteins due to monoclonal antibodies loss through an inflamed gut 19 and in such patients, the use of a nonprotein-based therapy for induction of remission, such as a CNI, could be useful.
The current study adds confidence to using the approach of inducing remission with CNIs-which are potent and fast-acting drugs with proven efficacy in treating patients with severe ulcerative colitis 3, [5] [6] [7] [8] 17, 18, 20 and then transitioning to the slower acting steroid-sparing agentvedolizumab, for maintenance therapy. 9, 10 We have shown that overlapping these two drugs is effective and safe.
This study adds to the armamentarium of therapeutic interventions available to physicians treating patients with severe steroid-refractory ulcerative colitis.
There are several limitations to our study, mainly linked to its retrospective single-centre setting with the inherent risk of bias, and incomplete data for some patients. Treatments were not standardised, and the side effects of drugs may have been underestimated. It should also be emphasised that patients were treated by expert physicians in a large referral centre.
In conclusion, induction of remission with CNIs with a transition to vedolizumab is effective and safe and leads to avoidance of colectomy in a substantial subgroup of patients over a long follow-up period. Such a treatment strategy might be considered in patients with steroid-refractory colitis, especially if they had previously failed either anti-TNFs or thiopurines. Such a strategy enables the introduction of safe protein-based therapies such as vedolizumab following stabilisation and induction of remission with CNIs.
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